BioStock: Annexin’s CEO on ANXV’s potential and the plan for 2022

Biotechnology company Annexin Pharmaceuticals is approaching the initiation of a phase II study after positive phase I results and an established large-scale production of its primary drug candidate ANXV. The company’s goal is to position the candidate as First-In-Class, with vascular diseases as the targeted indication. BioStock has spoken with CEO Anders Haegerstrand to find out more about the company and its ambitions for 2022.

Read the full interview with Anders Haegerstrand at biostock.se:

https://www.biostock.se/en/2022/04/annexins-ceo-on-anxvs-potential-and-the-plan-for-2022/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/